$72.50 -$1.18 (-1.6%)

04:00 PM EST on 11/22/19

Bluebird Bio Inc. (NASDAQ:BLUE)

CAPS Rating: 4 out of 5

Current Price $72.50 Mkt Cap $4.1B
Open $73.92 P/E Ratio 0.00
Prev. Close $73.68 Div. (Yield) $0.00 (0.0%)
Daily Range $71.42 - $74.35 Volume 2,260,049
52-Wk Range $71.42 - $163.43 Avg. Daily Vol. 1,003,070


How do you think NASDAQ:BLUE will perform against the market?

Add Stock to CAPS Watchlist

All Players

259 Outperform
17 Underperform

All-Star Players

85 Outperform
6 Underperform

Wall Street

6 Outperform
0 Underperform

Top NASDAQ:BLUE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFSaintCroix (98.97)
Submitted February 14, 2018

I am very impressed with Nick Leschly. You can watch his Ted Talk here:https://www.youtube.com/watch?v=Ez560GnkSrE

TMFFlygal (99.41)
Submitted December 08, 2015

Selling for a while after the huge drop today, good for a trade


Fools bullish on NASDAQ:BLUE are also bullish on:

Fools bearish on NASDAQ:BLUE are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BLUE.


Member Avatar SurfingCabarete (24.86) Submitted: 7/9/2019 12:18:18 PM : Outperform Start Price: $131.71 NASDAQ:BLUE Score: -49.74

another bet on gene editing


Member Avatar jbonefish (54.50) Submitted: 6/14/2019 10:51:02 PM : Outperform Start Price: $118.05 NASDAQ:BLUE Score: -46.00

In the “age of miracles” Bluebird is out in front in applying the science and focused on the types of diseases (single gene mutations) that are most likely to result in breakthrough treatments initially. Rather than being a good moonshot story, BLUE is doing the work that will solve problems for patients - that is a better recipe for long term financial success than a good story.


Member Avatar MarkFitzFool (41.53) Submitted: 5/11/2019 12:39:01 PM : Outperform Start Price: $132.45 NASDAQ:BLUE Score: -55.37

$BLUE is a leader in the new wave, the future, of personalized genomic therapies based on both gene editing and immunotherapy. They're ahead of Edits when it comes to bringing their Beta-Thalassemia and Sickle Cell Disease therapies to market. Mark my words, they will be the first to market with those therapies (although there is room for several players in the space). They have impressive partnerships with Regeneron, Celgene, Boston Children's Hospital, Seattle Children's Hospital, etc. I know from speaking to some senior scientists at the company, that they plan to file FDA approval for at least four candidate therapies within the next two years. Beta-Thalassemia approval in the EU will likely come first. Is it a risky investment? Yes, a bit, as is the nature of virtually all developmental and pre-clinical stage biotechs, but they are a true leader, and I don't see them going away or failing anytime soon.


Find the members with the highest scoring picks in BLUE.

Score Leader


DoubleBagel (33.19) Score: +669.10

The Score Leader is the player with the highest score across all their picks in BLUE.

Member Name Member
Call Time
Score Commentary
portefeuille12 29.24 4/16/2014 Outperform 5Y $19.11 +279.38% +67.46% +211.92 0 Comment
portefeuille2 98.78 4/11/2014 10/31/2019 Outperform 5Y $20.74 +249.57% +70.96% +178.60 0 Comment
portefeuille3 97.02 4/11/2014 Outperform 5Y $20.74 +249.57% +71.10% +178.46 0 Comment
johninmadison 81.66 4/7/2014 Outperform 5Y $21.07 +244.09% +67.28% +176.81 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 98.22 11/5/2013 Outperform 5Y $20.53 +253.14% +76.67% +176.47 0 Comment
portefeuille6 99.36 4/11/2014 Outperform 5Y $20.91 +246.72% +71.33% +175.39 0 Comment
HoosierDoozer < 20 2/5/2014 Outperform 5Y $20.84 +247.89% +77.92% +169.97 0 Comment
portefeuille 98.35 4/8/2014 Outperform 5Y $21.44 +238.15% +68.70% +169.45 1 Comment
jack0071 71.07 1/8/2014 Outperform 5Y $21.47 +237.68% +69.52% +168.16 0 Comment
jtothes 72.84 2/14/2014 Outperform 3Y $21.88 +231.35% +70.08% +161.27 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BLUE.